We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
+82.83%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$104M
AUM Growth
–
Cap. Flow
+$89.1M
Cap. Flow
% of AUM
85.97%
Top 10 Holdings %
Top 10 Hldgs %
53.66%
Holding
49
New
49
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRFS
Grifois
GRFS
|
+$9.87M |
| 2 |
EPIX
ESSA Pharma
EPIX
|
+$7.6M |
| 3 |
WMGI
Wright Medical Group Inc
WMGI
|
+$5.94M |
| 4 |
AGN
Allergan plc
AGN
|
+$5.14M |
| 5 |
Spyre Therapeutics
SYRE
|
+$3.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.31% |
| 2 | Real Estate | 0.65% |
| 3 | Communication Services | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRFS
1
Grifois
GRFS
$5.33B
| $10.5M | 10.17% |
+452,900
| New | +$9.87M |
|
|
EPIX
2
DELISTED
ESSA Pharma
EPIX
| $8.99M | 8.67% |
+1,634,369
| New | +$7.6M |
|
|
WMGI
3
DELISTED
Wright Medical Group Inc
WMGI
| $6.91M | 6.66% |
+226,700
| New | +$5.94M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.73M | 5.53% |
+668,371
| New | +$2.39M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $5.45M | 5.25% |
+28,500
| New | +$5.14M |
|
|
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
| $3.95M | 3.81% |
+34,280
| New | +$3.02M |
|
7
DexCom
DXCM
$28.7B
| $3.85M | 3.71% |
+70,400
| New | +$3.34M |
|
|
8
Spyre Therapeutics
SYRE
$8.72B
| $3.5M | 3.38% |
+18,327
| New | +$3.6M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.38M | 3.26% |
+31,300
| New | +$3.35M |
|
|
MSON
10
DELISTED
Misonix Inc
MSON
| $3.32M | 3.21% |
+178,596
| New | +$3.27M |
|
11
iRadimed
IRMD
$1.23B
| $3.29M | 3.17% |
+140,752
| New | +$3.29M |
|
12
Vericel Corp
VCEL
$2.33B
| $3.2M | 3.08% |
+183,680
| New | +$3.13M |
|
|
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.06M | 2.95% |
+6,847
| New | +$2.43M |
|
14
Establishment Labs
ESTA
$2.72B
| $2.59M | 2.5% |
+93,560
| New | +$2.07M |
|
|
DERM
15
DELISTED
Dermira, Inc.
DERM
| $2.5M | 2.41% |
+164,600
| New | +$1.42M |
|
16
Axogen
AXGN
$2.17B
| $2.28M | 2.2% |
+127,450
| New | +$1.88M |
|
17
Biogen
BIIB
$30B
| $2.23M | 2.15% |
+7,500
| New | +$2.08M |
|
18
Humana
HUM
$46B
| $2.13M | 2.05% |
+5,800
| New | +$1.84M |
|
19
Xenon Pharmaceuticals
XENE
$6.37B
| $2.12M | 2.04% |
+161,600
| New | +$1.7M |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $2.11M | 2.04% |
+26,400
| New | +$1.98M |
|
|
CNST
21
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $1.98M | 1.91% |
+42,100
| New | +$1.22M |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $1.84M | 1.77% |
+188,800
| New | +$1.73M |
|
|
HARP
23
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $1.82M | 1.76% |
+12,320
| New | +$1.87M |
|
|
KDMN
24
DELISTED
Kadmon Holdings, Inc.
KDMN
| $1.59M | 1.53% |
+350,300
| New | +$1.28M |
|
25
CRISPR Therapeutics
CRSP
$4.66B
| $1.36M | 1.31% |
+22,300
| New | +$1.22M |
|
Similar funds
TW
JC
M
SG
BW
BL
FFA
GWM
Soleus Capital Management's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for Soleus Capital Management, which disclosed 49 positions worth $104M. Its ten largest holdings account for 54% of the portfolio.
Its largest position is Grifois: 452,900 shares worth $10.5M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, followed by Real Estate and Communication Services.
- Soleus Capital Management's largest Q4 2019 buy was Grifois: 452,900 shares worth $10.5M.
- Soleus Capital Management's ten largest holdings make up 54% of its $104M portfolio in Q4 2019.
- Soleus Capital Management disclosed 49 positions in Q4 2019, its first 13F filing on record.
Based on Soleus Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.